Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$54.92M+183.49%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Amir London
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 462
- Beta
- 0.14
- Country
- IL
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.64
Financials
Revenue
$54.92M+183.5%Net Income
$9.26MEBITDA
$13.40MFree Cash Flow
$15.96MEPS (diluted)
$0.16Shares Outstanding (diluted)
57.89M+66.8%Operating Expenses
$12.96MCash & Debt
$70.13MReturn of Capital
$14.42MRevenue by Segment (annual)
$24.25MDividend per Share
$0.17Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $180.46M | $20.20M | $0.38 |
| 2024 | $160.95M | $14.46M | $0.25 |
| 2023 | $142.52M | $8.28M | $0.17 |
| 2022 | $129.34M | $-2.32M | $-0.05 |
| 2021 | $103.64M | $-2.23M | $-0.05 |
| 2020 | $133.25M | $17.14M | $0.42 |
| 2019 | $127.19M | $22.25M | $0.57 |
| 2018 | $114.47M | $22.30M | $0.55 |
| 2017 | $102.83M | $6.90M | $0.18 |
| 2016 | $77.49M | $-6.73M | $-0.18 |
| 2015 | $70.11M | $-11.27M | $-0.31 |
| 2014 | $71.92M | $-12.64M | $-0.35 |
| 2013 | $70.62M | $443.0K | $0.01 |
| 2012 | $72.67M | $260.0K | $0.01 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from KMDA's reported EPS growth of 32.3% a year over 13 years. Historical EPS growth of 32% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $1.30
- Implied price
- $24.72
- Return from $8.31
- 24.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $12.29 — today's price is already 32.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| 20.0% | 6.4% | 10.9% | 14.8% | 18.2% | 21.3% |
| 25.0% | 10.8% | 15.5% | 19.6% | 23.1% | 26.3% |
| 30.0% | 15.3% | 20.2% | 24.4% | 28.1% | 31.4% |
| 35.0% | 19.7% | 24.8% | 29.1% | 33.0% | 36.4% |
| 40.0% | 24.1% | 29.4% | 33.9% | 37.9% | 41.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-68.75%Social Signal Score
Mentions (10)
- Newsmarketbeat.com·9d ago·Neutral
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth Kamada NASDAQ: KMDA outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply and potential acquisitions.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
…o Present at the H.C. Wainwright 28th Annual Global Investment Conference REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conf…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
…ures on Previously Announced Cash Dividend to Shareholders REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $…
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy
View source ↗ - Newszacks.com·52d ago·Positive
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes" Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·52d ago·Positive
KMDA or PRTA: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·54d ago·Neutral
Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsglobenewswire.com·55d ago·Positive
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced fi
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Kamada Announces Planned Transition of Chief Financial Officer REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that Chaime Orlev, its Chief Financial Officer (CFO), will transition out of his role to pursue other opportunities, effective Dece
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $0.13 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$0.16 vs $0.11beat
- Wed, May 13$0.07 vs $0.12miss
- Wed, Mar 11$0.06 vs $0.09miss
- Mon, Nov 10$0.09 vs $0.10miss
- Wed, Aug 13$0.13 vs $0.09beat
- Wed, May 14$0.07 vs $0.07beat
Estimates and results for KMDA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KMDA officers and directors.
- Bought
- —
- Sold
- $1.7m
0 trades
4 trades
- Tsur Davidsold
- Tsur Davidsold
- Tsur Davidsold
- Tsur Davidsold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KMDA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.